{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:23:49Z","timestamp":1782512629675,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.thromres.2014.06.034","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T23:30:16Z","timestamp":1405121416000},"page":"693-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["SAR216471, an alternative to the use of currently available P2Y12 receptor inhibitors?"],"prefix":"10.1016","volume":"134","author":[{"given":"N.","family":"Delesque-Touchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Pflieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bonnet-Lignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Salel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Boldron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Savi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.06.034_bb0005","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.06.034_bb0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2014.06.034_bb0015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138161206776361318","article-title":"Biology and pharmacology of the platelet P2Y12 receptor","volume":"12","author":"Storey","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.thromres.2014.06.034_bb0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/heart.85.1.92","article-title":"Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement","volume":"85","author":"M\u00fcller","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2014.06.034_bb0025","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.06.034_bb0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.06.034_bb0035","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.06.034_bb0040","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.06.034_bb0045","author":"US Food and Drug Administration"},{"key":"10.1016\/j.thromres.2014.06.034_bb0050","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.amjcard.2009.12.052","article-title":"Mortality in the TRITON trial: update from the FDA prasugrel action package","volume":"105","author":"Serebruany","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2014.06.034_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.06.034_bb0060","first-page":"115","article-title":"Use of radiolabeled 2-methylthio-ADP to study P2Y receptors on platelets and cell lines","volume":"273","author":"Savi","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.thromres.2014.06.034_bb0065","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2307\/2531207","article-title":"Choosing near-linear parameters in the four-parameter log model for radioligand and related assays","volume":"42","author":"Ratkowsky","year":"1986","journal-title":"Biometrics"},{"key":"10.1016\/j.thromres.2014.06.034_bb0070","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2014.06.034_bb0075","first-page":"73","article-title":"Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats","volume":"39","author":"Umetsu","year":"1978","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.034_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5482\/HAMO-12-12-0022","article-title":"Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome","volume":"33","author":"Sibbing","year":"2013","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.thromres.2014.06.034_bb0085","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","article-title":"Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-elevation acute coronary syndrome","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.06.034_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.06.034_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5482\/HAMO-12-05-0003","article-title":"Antiplatelet therapy \u2013 ticagrelor","volume":"32","author":"Giannitsis","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.thromres.2014.06.034_bb0100","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/01.CIR.0000137972.74120.12","article-title":"Loading with 600mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy","volume":"110","author":"Kastrati","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.06.034_bb0105","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1538-7836.2010.03809.x","article-title":"Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis","volume":"8","author":"Combescure","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.034_bb0110","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.06.034_bb0115","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.jacc.2007.07.051","article-title":"Platelet function monitoring in patients with coronary artery disease","volume":"50","author":"Gurbel","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.06.034_bb0120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.06.034_bb0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4244\/51","article-title":"Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?","volume":"5","author":"Cuisset","year":"2009","journal-title":"EuroIntervention"},{"key":"10.1016\/j.thromres.2014.06.034_bb0130","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","article-title":"Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement","volume":"8","author":"Sibbing","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.034_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/617098","article-title":"Towards personalized medicine based on platelet function testing for stent thrombosis patients","volume":"2012","author":"Godschalk","year":"2012","journal-title":"Thrombosis"},{"key":"10.1016\/j.thromres.2014.06.034_bb0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12265-013-9458-z","article-title":"Platelet Function Testing and Tailored Antiplatelet Therapy","volume":"6","author":"Janssen","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.thromres.2014.06.034_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH09-07-0482","article-title":"Bal dit Sollier C, Barth\u00e9l\u00e9my O, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome: the randomised, double-blind ACAPULCO study","volume":"103","author":"Montalescot","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.034_bb0150","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814003600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814003600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T05:56:33Z","timestamp":1689400593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814003600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0049384814003600"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.06.034","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SAR216471, an alternative to the use of currently available P2Y12 receptor inhibitors?","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}